TransDerm Inks Research Deal with RXi, Gets Grant to Explore Delivery Technologies
April 08, 2010
TransDerm Inks Research Deal with RXi, Gets Grant to Explore Delivery Technologies
In addition to evaluating RXi's proprietary RNAi compounds, TransDerm will test delivery technologies from Traversa Therapeutics, Thermo Fisher Scientific, and Life Technologies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Thermo Fisher Acquiring Life Tech, RNAi Reagent Space Consolidates Further
April 18, 2013 / Gene Silencing News - TransDerm Preps for New Phase I Trial with New RNAi Drug, Delivery System
June 7, 2012 / Gene Silencing News - TransDerm Awarded $4M Grant to Develop RNAi Treatment for Skin Disease
September 29, 2011 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - RXi Inks Ocular Disease Collaboration with UMMS
January 14, 2010 / Gene Silencing News